Barabio Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$4.33M
- Investors
-
2
Barabio General Information
Description
Operator of a biotech company intended to develop drugs. The company develops next-generation anticancer drugs for cancer patients and provide diagnostic kits using metabolic diseases, muscle-related biomarkers, and establishing a digital healthcare platform and aims to become the first mover in the global anticancer drug market by presenting a new paradigm of metabolic anticancer drugs, enabling business to provider a drug to cure diseases.
Contact Information
Website
www.barabio.co.krCorporate Office
- 418, 20, Eonju-ro 63-gil
- Gangnam-gu
- Seoul
- South Korea
Corporate Office
- 418, 20, Eonju-ro 63-gil
- Gangnam-gu
- Seoul
- South Korea
Barabio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 10-Jul-2024 | $4.33M | Completed | Startup | ||
| 1. Seed Round | 01-Sep-2021 | Completed | Startup |
Barabio FAQs
-
When was Barabio founded?
Barabio was founded in 2021.
-
Where is Barabio headquartered?
Barabio is headquartered in Seoul, South Korea.
-
What industry is Barabio in?
Barabio’s primary industry is Drug Discovery.
-
Is Barabio a private or public company?
Barabio is a Private company.
-
What is the current valuation of Barabio?
The current valuation of Barabio is .
-
What is Barabio’s current revenue?
The current revenue for Barabio is .
-
When was Barabio acquired?
Barabio was acquired on 10-Jul-2024.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process